Home » Newsletters » BioWorld Science

BioWorld Science

June 18, 1998

View Archived Issues

MitoKor and UCSF collaborate on Alzheimer's disease research

Guilford seeks licensing partner for Parkinson's disease diagnostic tool

Guilford offering two lead neuroprotective programs for licensing

Orally active and potent GH secretagogue discovered by Merck & Co.

Long-term financing plan for Genzyme Tissue Repair revealed

P&U identifies potent distamycin derivatives with improved therapeutic indices

Oncolym makes progress in phase II

Company Profile: Genome Pharmaceuticals

Final HOT Study results announced

Ebelactone B, a urinary kininase inhibitor, prevents salt-related hypertension in rats

Melatonin effective therapy for headache in patients with sleep phase delay syndrome

Antidiabetic activity of S-3483, a site-specific inhibitor of Glc-6-Pase

ABT-761: relationship between effect on exercise-induced bronchoconstriction and 5-LO inhibition

Dompe's novel antihistamine in phase I testing

Dual-action ACE/NEP inhibitors in the pipeline at Zambon

Research into new tocolytic agents continues at Merck & Co.

New HIV protease inhibitors reported by Searle

Kyowa Hakko claims new agents for thrombocytopenia

Irish research organization discovers MAO inhibitor with cytoprotective effects

Adolor in-licenses Roberts compound for narcotic-induced constipation

Abarelix poised to enter phase III clinical development

Famvir cleared by FDA for treatment of herpes in HIV-positive individuals

NDA submitted for new lung tumor imaging agent from Diatide

Angiotech's micellar paclitaxel enters clinic for arthritis

Second trial begins for DTI-136 in the treatment of liver cancer

Phase IIb results presented for pulmonary insulin

Zonagen reaches milestone for Vasomax

Karo Bio and the University of California expand license agreement

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...